9-tert-butyl-acridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 9-tert-butyl-acridine
• 英文别名: 9-tert-Butyl-acridin；Acridine, 9-t-butyl-；9-tert-butylacridine
• 化学式: C₁₇H₁₇N
• 分子量: 235.329
• InChiKey: CERFTYQSYPLRFX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  二苯胺 、 三甲基乙酸 在 zinc(II) chloride 作用下， 生成 9-tert-butyl-acridine
  参考文献：
  名称：

  Buu-Hoi; Lecocq, Recueil des Travaux Chimiques des Pays-Bas, 1945, vol. 64, p. 250,253

  摘要：

  DOI：

文献信息

• INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE
  申请人：Board of Regents, The University of Texas System

  公开号：US20210154204A1

  公开（公告）日：2021-05-27

  Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.

  本文披露了抑制RIPK1的化合物，包括药物组合物和治疗RIPK1介导的疾病的方法，如神经退行性疾病、炎症性疾病和癌症。
• STAT3 INHIBITOR
  申请人：BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

  公开号：US20150361031A1

  公开（公告）日：2015-12-17

  Provided are STAT3 inhibitors and methods of treating inflammation or a hyperproliferative disease such as, e.g., cancer. In some aspects, compounds may be used to treat breast cancer, a head/neck cancer, a lung cancer, a prostate cancer, or pancreatic cancer.

  提供了STAT3抑制剂和治疗炎症或过度增殖疾病（例如癌症）的方法。在某些方面，化合物可用于治疗乳腺癌、头颈癌、肺癌、前列腺癌或胰腺癌。
• Nitrogen-containing polycyclic compound and organic light emitting device using same
  申请人：LG CHEM, LTD.

  公开号：US10035765B2

  公开（公告）日：2018-07-31

  The present specification provides a multicyclic compound including nitrogen and an organic light emitting device using the same.

  本说明书提供了一种含氮的多环化合物以及使用该化合物的有机发光器件。
• 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION
  申请人：Phadke Avinash

  公开号：US20100216725A1

  公开（公告）日：2010-08-26

  The invention provides 4-amino-4-oxobutanoyl peptides of Formula I and the pharmaceutically salts and hydrates thereof. The variables R, R 1 , R 6 -R 8 , R 16 , R 18 , R 19 , M, n, T, Y, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. The 4-amino-4-oxobutanoyl peptides disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptides and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain a 4-amino-4-oxobutanoyl peptides as the only active agent or may contain a combination of a 4-amino-4-oxobutanoyl peptides and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections.
• NEW 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION
  申请人：Phadke Avinash

  公开号：US20140113890A1

  公开（公告）日：2014-04-24

  The invention provides 4-amino-4-oxobutanoyl peptides of Formula I and the pharmaceutically salts and hydrates thereof. The variables R, R 1 , R 6 -R 8 , R 16 , R 18 , R 19 , M, n, T, Y, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. The 4-amino-4-oxobutanoyl peptides disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptides and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain a 4-amino-4-oxobutanoyl peptides as the only active agent or may contain a combination of a 4-amino-4-oxobutanoyl peptides and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections.